LM-168 + toripalimab

**LM-168 + toripalimab** is an investigational co-administration regimen being evaluated by LaNova Medicines in patients with advanced solid tumours. LM-168 is an ANP-conditional anti-CTLA-4 monoclonal antibody engineered to preferentially bind and inhibit CTLA-4 in the ATP, ADP, and AMP-rich tumour microenvironment, with the aim of reducing peripheral on-target toxicity. Toripalimab is a humanized anti-PD-1 monoclonal antibody that prevents PD-1 interaction with PD-L1 and PD-L2. Dual CTLA-4 and PD-1 checkpoint blockade is intended to enhance antitumour T-cell activation through complementary immune-checkpoint mechanisms. The regimen is being studied in the Phase I/II trial NCT06868199 for advanced solid tumours. ([aacrjournals.org](https://aacrjournals.org/cancerres/article/85/8_Supplement_1/6065/761060/Abstract-6065-Preclinical-evaluation-of-LM-168-A))

Other names

LM 168 + toripalimabLM-168 + toripalimabLM168 + toripalimab